Eris Lifesciences Limited
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as antiΒdiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Operating margin of 30.7% exceeds Healthcare median (24.8%)
Concerns1
- Operating margin declining for 3 consecutive years (38.0% β 31.0% β 29.0%)
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ1.70 K Cr | β | βΉ77.00 Cr | β | β | 3.1% | 14.2% | -74.3% |
| Mar 2024 | βΉ1.49 K Cr | β | βΉ300.00 Cr | β | β | 11.9% | 11.7% | -24.6% |
| Mar 2023 | βΉ1.33 K Cr | β | βΉ398.00 Cr | β | β | 17.9% | 9.5% | -4.6% |
| Mar 2022 | βΉ1.22 K Cr | β | βΉ417.00 Cr | β | β | 21.7% | 9.6% | 18.8% |
| Mar 2021 | βΉ1.11 K Cr | β | βΉ351.00 Cr | β | β | 22.3% | 8.7% | 20.6% |
| Mar 2020 | βΉ1.02 K Cr | β | βΉ291.00 Cr | β | β | 22.4% | 13.7% | 2.1% |
| Mar 2019 | βΉ897.00 Cr | β | βΉ285.00 Cr | β | β | 24.7% | 17.9% | -3.1% |
| Mar 2018 | βΉ761.00 Cr | β | βΉ294.00 Cr | β | β | 33.9% | 6.7% | 18.5% |
| Mar 2017 | βΉ713.00 Cr | β | βΉ248.00 Cr | β | β | 43.1% | 17.9% | 79.7% |
| Mar 2016 | βΉ605.00 Cr | β | βΉ138.00 Cr | β | β | 45.2% | 10.4% | 66.3% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 2,034 |
| Total Expenses | 1,300 |
| EBIT / Operating Profit | 734 |
| OPM % | 36% |
| Other Income | 71 |
| Finance Costs | 199 |
| Depreciation & Amortisation | 167 |
| Profit Before Tax | 438 |
| Tax % | - |
| Net Profit / PAT | 282 |
| EPS (βΉ) | 20.69 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Eris Lifesciences Limitedthis co. | βΉ20.13 K Cr | βΉ1.70 K Cr | 71.40 | 7.28 | 45.52 | 14.2% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |